Phase II
Pfizer announced results from its Phase IIa clinical trial of PF-06651600 and PF-06700841 in alopecia areata (AA).
Optimized production process delivering critical improvements for future commercial use to be applied to all allogeneic platform clinical trials
Supernus Pharmaceutical, headquartered in Rockville, Maryland, is acquiring Biscayne Neurotherapeutics, located in Miami, Florida.
Without a doubt China has become one of the most important markets for pharma companies, given the vast patient population and the rising cancer rates. And it seems that western pharmaceutical companies are making greater inroads there.
BTX 1503 acne Phase 2 clinical trial currently underway across US and Australian sites with data expected in mid-CY2019
Gilead Sciences had a lot of news lately. First off, Gilead and Belgium-based Galapagos NV announced results from their FINCH 2 Phase III clinical trial of filgotinib in adults with moderately-to-severely active rheumatoid arthritis.
Bristol-Myers Squibb announced that its Phase II clinical trial of BMS-986165 for moderate to severe plaque psoriasis hit its efficacy endpoints.
6 of 8 pts (75%) ORR in treatment-naïve EGFR mutation-positive NSCLC patients Well-tolerated with unremarkable safety profile; No DLTs or related SAEs
EpicGenetics and Massachusetts General Hospital (MGH) are launching a Phase II clinical trial to test a tuberculosis vaccine, BCG, as a potential treatment for fibromyalgia.
The first stage of the Phase IIa study with YELIVA® for advanced cholangiocarcinoma (bile duct cancer), a highly lethal malignancy, achieved its pre-specified efficacy goal, and the study can therefore continue to its second stage, enrolling the full cohort of 39 evaluable patients who previous received other treatments
PRESS RELEASES